Log In
Print
BCIQ
Print
Print this Print this
 

JR-032

  Manage Alerts
Collapse Summary General Information
Company JCR Pharmaceuticals Co. Ltd.
DescriptionRecombinant iduronate-2-sulfatase rDNA origin manafactured using serum-free culture technology
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation

Partner

GlaxoSmithKline plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today